Stimulant AbuseNCT05845333
Neurocognitive Abnormalities in Stimulant Abuse Among High-Risk Women
An observational study of Stimulant Abuse and Criminal Behavior, run by The Mind Research Network at 1 site in United States.
Trial summary
Substance use disorders and psychopathy are serious and costly mental health issues. Psychopathy is known to be associated with aberrant moral decision making and there is considerable interest in determining whether substance use disorders lead to impairments in these same cognitive processes. Read more about this study
- Who is it for?
- Ages 18 to 70 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Stimulant Abuse, Criminal Behavior
- What is being tested?
- Decision task
- How many people
- 334 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2022to 31 May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Incarcerated and non-incarcerated adult women
Who may be able to join
- Biological sex is female
- Intelligence Quotient 70 or higher
- Reading level 5th grade or higher
- Able to speak and understand English
Who cannot join
- Uncorrectable auditory or visual deficits
- Currently pregnant
- MRI contraindication
- Central nervous system disease
- Current major medical condition
- Hypertension with complications (e.g., stroke)
Show all 14Show fewer
- Diabetes with complications
- Lifetime history of psychotic disorder
- Self-report of psychotic disorder (with psychiatric hospitalization) in first degree relative
- Drug use in past three months
- (Healthy controls only):
- History of arrest
- Substance use beyond light alcohol or marijuana use
- Currently taking psychotropic medications
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The Mind Research Network
Albuquerque, New Mexico, 87106
Carla Harenski, 505-272-5028, charenski@mrn.org
About this study
Substance use disorders and psychopathy are serious and costly mental health issues. Psychopathy is known to be associated with aberrant moral decision making and there is considerable interest in determining whether substance use disorders lead to impairments in these same cognitive processes. Recent large-scale research initiatives in forensic settings have begun to identify substance abuse and psychopathy-related disruption in the neural mechanisms involved in moral decision-making processes, and associations between these neural networks and future relapse and antisocial behavior. Here the investigators extend prior work (with incarcerated men) to examine these issues among incarcerated women in order to better understand sex differences. This project addresses the overall lack of neurocognitive research in criminal offenders with substance use disorders, thereby focusing on a major public health issue in an underserved and understudied population.
Read the detailed description
There continues to be great interest and public health relevance with regard to understanding the neurobiological systems that underlie the comorbidity of substance use disorders and other psychiatric conditions. In a previous award, efforts were focused upon characterizing the neural circuitry underlying moral decision making in incarcerated men with varying levels of two frequently co-occurring conditions: stimulant abuse and psychopathy. Here this work will be extended to incarcerated women, to examine longitudinal outcomes and apply state-of-the-art network analyses for predictive models. Prior studies have demonstrated sex differences in the degree and expression of psychopathic traits, patterns of stimulant abuse, and moral decision-making. However, the neural circuitry that underlies these sex differences is not well understood. Substantial sex differences in regional gray matter volume and density in extant samples have also been identified. Collectively, sex differences in pathophysiology could have significant implications for treatment strategies and differential biomarkers of treatment prediction and outcome in men and women. The investigators will implement the research strategy with a large incarcerated population by deploying a unique mobile MRI scanner to the regional women's prison. Participants will be stratified by level of lifetime stimulant (cocaine, amphetamine) use severity and psychopathic traits (high, medium, low) and will undergo anatomical and functional MRI scanning while completing multi-modal (i.e., linguistic and picture) decision-making tasks. Results will be compared to those obtained in a prior award (incarcerated men, n>300). Functional network and dynamic network connectivity will also be examined in women using a new multiband echo planar imaging (EPI) pulse sequence, and longitudinal outcomes after release to the community will be collected to test behavioral and neuropredictive models of relapse and future antisocial behavior. This work is expected to generate a large, robust dataset that characterizes the overlapping and unique aspects of neural circuitry underlying stimulant use and psychopathy in females and males. The proposed research is in line with recent priorities emphasized by the National Institute on Drug Abuse (NIDA) for projects aimed at examining male-female differences, and effects specific to females, to improve understanding of the nature and etiology of drug abuse.
- Conditions
- Stimulant Abuse, Criminal Behavior
- Being tested
- Decision task
- Medical subject headings
- Criminal Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Decision taskOther
Participants will complete a simple and/or moral decision making functional MRI task.
| Study group | Role | What they receive |
|---|---|---|
| Stimulant Use Severity High | Not described Receives: Other: Decision task | |
| Stimulant Use Severity Medium | Not described Receives: Other: Decision task | |
| Stimulant Use Severity Low | Not described Receives: Other: Decision task | |
| Psychopathic Traits High | Not described Receives: Other: Decision task | |
| Psychopathic Traits Medium | Not described Receives: Other: Decision task | |
| Psychopathic Traits Low | Not described Receives: Other: Decision task | |
| Community (Healthy) Controls | Not described Receives: Other: Decision task |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gray matter volume during MRI scan & stimulant use
Gray matter volume (using relevant MRI analysis platforms - Statistical Parametric Mapping/SPM) correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
White matter integrity during MRI scan & stimulant use
White matter integrity (using relevant MRI analysis platforms - Functional Magnetic Resonance Imaging of the Brain software library (FSL)) correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional brain response during MRI scan & stimulant use during simple linguistic decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional brain response during MRI scan & stimulant use during simple picture decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional brain response during MRI scan & stimulant use during moral linguistic decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional brain response during MRI scan & stimulant use during moral picture decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional connectivity during MRI scan & stimulant use during simple linguistic decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional connectivity during MRI scan & stimulant use during simple picture decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional connectivity during MRI scan & stimulant use during moral linguistic decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Functional connectivity during MRI scan & stimulant use during moral picture decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Measured: During MRI procedure
Gray matter volume during MRI scan & psychopathic traits
Gray matter volume (using relevant MRI analysis platforms - Statistical Parametric Mapping/SPM) correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
White matter integrity during MRI scan & psychopathic traits
White matter integrity (using relevant MRI analysis platforms - Functional Magnetic Resonance Imaging of the Brain software library (FSL)) correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional brain response during MRI scan & psychopathic traits during simple linguistic decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional brain response during MRI scan & psychopathic traits during simple picture decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional brain response during MRI scan & psychopathic traits during moral linguistic decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional brain response during MRI scan & psychopathic traits during moral picture decision task
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional connectivity during MRI scan & psychopathic traits during simple linguistic decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional connectivity during MRI scan & psychopathic traits during simple picture decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT)) during Simple Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional connectivity during MRI scan & psychopathic traits during moral linguistic decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Functional connectivity during MRI scan & psychopathic traits during moral picture decision task
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Measured: During MRI procedure
Relapse to/change in stimulant use post-release
Return to stimulant use (assessed using timeline follow back calendar (TLFB)) post-release from incarceration
Measured: Every 3 months post release for duration of grant (5 years)
Return to/change in antisocial behavior post-release
Return to antisocial behavior (assessed via self report and/or official records) post-release from incarceration
Measured: Every 3 months post release for duration of grant (5 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2023
- Study start1 Aug 2022
- Primary completion31 May 2027 (estimated)
- Study completion31 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stimulant AbuseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 334 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Mind Research Network
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kent Kiehl, The Mind Research Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05845333
- Sponsor's protocol ID
- 15050
- Status last verified
- May 2025
- First submitted
- 7 Apr 2023
- Last updated
- 8 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neurocognitive Abnormalities in Stimulant Abuse Among High-Risk Women
- ClinicalTrials.gov ID
- NCT05845333
- Acronym / sponsor ID
- 15050
- Conditions
- Stimulant Abuse, Criminal Behavior
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 334 participants (estimated)
- Lead sponsor
- The Mind Research NetworkUniversity, hospital or other
- Study start
- 1 Aug 2022 (actual)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 31 May 2027 (estimated)
- First posted
- 6 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Substance use disorders and psychopathy are serious and costly mental health issues. Psychopathy is known to be associated with aberrant moral decision making and there is considerable interest in determining whether substance use disorders lead to impairments in these same cognitive processes. Recent large-scale research initiatives in forensic settings have begun to identify substance abuse and psychopathy-related disruption in the neural mechanisms involved in moral decision-making processes, and associations between these neural networks and future relapse and antisocial behavior. Here the investigators extend prior work (with incarcerated men) to examine these issues among incarcerated women in order to better understand sex differences. This project addresses the overall lack of neurocognitive research in criminal offenders with substance use disorders, thereby focusing on a major public health issue in an underserved and understudied population.
Detailed description
There continues to be great interest and public health relevance with regard to understanding the neurobiological systems that underlie the comorbidity of substance use disorders and other psychiatric conditions. In a previous award, efforts were focused upon characterizing the neural circuitry underlying moral decision making in incarcerated men with varying levels of two frequently co-occurring conditions: stimulant abuse and psychopathy. Here this work will be extended to incarcerated women, to examine longitudinal outcomes and apply state-of-the-art network analyses for predictive models. Prior studies have demonstrated sex differences in the degree and expression of psychopathic traits, patterns of stimulant abuse, and moral decision-making. However, the neural circuitry that underlies these sex differences is not well understood. Substantial sex differences in regional gray matter volume and density in extant samples have also been identified. Collectively, sex differences in pathophysiology could have significant implications for treatment strategies and differential biomarkers of treatment prediction and outcome in men and women. The investigators will implement the research strategy with a large incarcerated population by deploying a unique mobile MRI scanner to the regional women's prison. Participants will be stratified by level of lifetime stimulant (cocaine, amphetamine) use severity and psychopathic traits (high, medium, low) and will undergo anatomical and functional MRI scanning while completing multi-modal (i.e., linguistic and picture) decision-making tasks. Results will be compared to those obtained in a prior award (incarcerated men, n>300). Functional network and dynamic network connectivity will also be examined in women using a new multiband echo planar imaging (EPI) pulse sequence, and longitudinal outcomes after release to the community will be collected to test behavioral and neuropredictive models of relapse and future antisocial behavior. This work is expected to generate a large, robust dataset that characterizes the overlapping and unique aspects of neural circuitry underlying stimulant use and psychopathy in females and males. The proposed research is in line with recent priorities emphasized by the National Institute on Drug Abuse (NIDA) for projects aimed at examining male-female differences, and effects specific to females, to improve understanding of the nature and etiology of drug abuse.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Stimulant Use Severity High | – | Other: Decision task |
| Stimulant Use Severity Medium | – | Other: Decision task |
| Stimulant Use Severity Low | – | Other: Decision task |
| Psychopathic Traits High | – | Other: Decision task |
| Psychopathic Traits Medium | – | Other: Decision task |
| Psychopathic Traits Low | – | Other: Decision task |
| Community (Healthy) Controls | – | Other: Decision task |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Incarcerated and non-incarcerated adult women
Key inclusion criteria (4 listed)
- Biological sex is female
- Intelligence Quotient 70 or higher
- Reading level 5th grade or higher
- Able to speak and understand English
Key exclusion criteria (14 listed)
- Uncorrectable auditory or visual deficits
- Currently pregnant
- MRI contraindication
- Central nervous system disease
- Current major medical condition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Decision taskParticipants will complete a simple and/or moral decision making functional MRI task. | Other | Community (Healthy) Controls, Psychopathic Traits High, Psychopathic Traits Low, Psychopathic Traits Medium, Stimulant Use Severity High, Stimulant Use Severity Low, Stimulant Use Severity Medium |
Primary outcome
Gray matter volume during MRI scan & stimulant use
Time frame: During MRI procedure
Gray matter volume (using relevant MRI analysis platforms - Statistical Parametric Mapping/SPM) correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
White matter integrity during MRI scan & stimulant use
Time frame: During MRI procedure
White matter integrity (using relevant MRI analysis platforms - Functional Magnetic Resonance Imaging of the Brain software library (FSL)) correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional brain response during MRI scan & stimulant use during simple linguistic decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional brain response during MRI scan & stimulant use during simple picture decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional brain response during MRI scan & stimulant use during moral linguistic decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional brain response during MRI scan & stimulant use during moral picture decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional connectivity during MRI scan & stimulant use during simple linguistic decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional connectivity during MRI scan & stimulant use during simple picture decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional connectivity during MRI scan & stimulant use during moral linguistic decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Functional connectivity during MRI scan & stimulant use during moral picture decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)
Gray matter volume during MRI scan & psychopathic traits
Time frame: During MRI procedure
Gray matter volume (using relevant MRI analysis platforms - Statistical Parametric Mapping/SPM) correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
White matter integrity during MRI scan & psychopathic traits
Time frame: During MRI procedure
White matter integrity (using relevant MRI analysis platforms - Functional Magnetic Resonance Imaging of the Brain software library (FSL)) correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional brain response during MRI scan & psychopathic traits during simple linguistic decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional brain response during MRI scan & psychopathic traits during simple picture decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional brain response during MRI scan & psychopathic traits during moral linguistic decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional brain response during MRI scan & psychopathic traits during moral picture decision task
Time frame: During MRI procedure
Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional connectivity during MRI scan & psychopathic traits during simple linguistic decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional connectivity during MRI scan & psychopathic traits during simple picture decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT)) during Simple Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional connectivity during MRI scan & psychopathic traits during moral linguistic decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Functional connectivity during MRI scan & psychopathic traits during moral picture decision task
Time frame: During MRI procedure
Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)
Relapse to/change in stimulant use post-release
Time frame: Every 3 months post release for duration of grant (5 years)
Return to stimulant use (assessed using timeline follow back calendar (TLFB)) post-release from incarceration
Return to/change in antisocial behavior post-release
Time frame: Every 3 months post release for duration of grant (5 years)
Return to antisocial behavior (assessed via self report and/or official records) post-release from incarceration
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2025.
Related trials for Stimulant Abuse
Recruiting
rTMS for Craving in Methamphetamine Use Disorder
Methamphetamine Abuse, Substance Use Disorders
Recruiting
Project neuroARTEMIS
Stimulant Use, Human Immunodeficiency Virus (HIV)
Recruiting
Optimizing Pregnancy and Treatment Interventions for Moms 3.0
Opioid Abuse (Disorder), Stimulant Use Disorders
RecruitingPhase 2
Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
Methamphetamine Abuse, Methamphetamine-dependence
RecruitingPhase 2
Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
Methamphetamine Abuse, Methamphetamine-dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stimulant Abuse and Criminal Behavior, run by The Mind Research Network at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Carla Harenski (505-272-5028, charenski@mrn.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gray matter volume during MRI scan & stimulant use (time frame: During MRI procedure). The study lists 22 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2025.